EMA Backs Approval of Elahere for Ovarian Cancer

Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Medscape Medical News